Business Wire | May 7, 2021 07:00AM EDT

Bruker Corporation to Present at Investor Conferences

May 07, 2021

BILLERICA, Mass.--(BUSINESS WIRE)--May 07, 2021--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the following virtual conferences:

BofA Securities 2021 Health Care ConferenceTuesday, May 11, 2021, at 11:00 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Mark Munch, President, Bruker Nano Group

UBS Global Healthcare Virtual ConferenceMonday, May 24, 2021, at 9:00 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Mark Munch, President, Bruker Nano Group

Jefferies Virtual Healthcare ConferenceWednesday, June 2, 2021, at 8:00 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Juergen Srega, President, Bruker CALID Group

Live audio webcasts of the virtual presentation and "fireside" sessions will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays will be posted on Bruker's Investor Relations website after each event and will be available for 30 days following the presentation.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210507005145/en/

CONTACT: Miroslava Minkova Senior Director, Investor Relations & Corporate Development Bruker Corporation T: +1 (978) 663 - 3660, ext. 1479 E: Investor.Reations@bruker.com